Several new treatments for pancreatic cancer are on the horizon, including the PanCAN Early Detection Initiative and Auceliciclib. Several clinical trials are currently underway, testing new combinations of chemotherapy drugs. Read on to learn more about these treatments. In the meantime, read up on the latest developments. Here are some of the most promising:
PanCAN Early Detection Initiative
The new PanCAN Early Detection Initiative for the development of a new treatment for pancreatic cancer was announced by the National Cancer Institute on May 15, 2018. The study, called PanCAN-EDI, will study how to detect pancreatic cancer early when it can lead to an eight to 16-fold increase in survival rates. The researchers involved in the study include statisticians, clinicians, and diagnostic specialists.
CD40 agonist antibodies
CD40 agonist antibodies may help the immune system drive an immune response to pancreatic cancer. These antibodies trigger antigen-presenting cells to "prime" T cells for the tumour-destroying attack. The drugs have been studied in metastatic pancreatic cancer patients and patients with early-stage disease. The researchers hope to find a way to make CD40 agonists more widely available and, eventually, a new treatment for pancreatic cancer.
Scientists at the University of South Australia (UniSA) are preparing to trial a new drug to treat pancreatic cancer - Auceliciclib. This drug targets CDK4 and CDK6 enzymes to disrupt the growth of pancreatic cancer cells. Because it is more effective and has fewer side effects than standard cancer treatments, it may be the subsequent breakthrough treatment for pancreatic cancer. Pancreatic cancer is among the most complex treatment types, and the survival rate is low. It is often diagnosed at a late stage, making early treatment difficult.
Distal pancreatectomy for pancreatic carcinoma is a novel treatment option for cancer of the pancreas. In a pancreas tumour, the head is removed along with the bile duct and the duodenum. A temporary drain is placed in the abdominal cavity to help the body recover. It is a highly invasive procedure that takes between two to four hours.
An mRNA vaccine is being tested in clinical trials for patients with advanced pancreatic cancer. It is designed to restore the body's immune system, thereby preventing cancerous cells from forming. But this new treatment may only be effective in early-stage cancer since most patients are diagnosed with the disease in the later stages. The trial aims to confirm these promising results in more extensive tests.